ABTI (Alterola Biotech) Current Ratio: 0.32 (As of Sep. 2024)


What is Alterola Biotech Current Ratio?

Alterola Biotech ABTI Current Ratio is 0.32 as of Sep. 2024.

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Alterola Biotech's current ratio for the quarter that ended in Sep. 2024 was 0.32.

Alterola Biotech has a current ratio of 0.32. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Alterola Biotech has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Alterola Biotech's Current Ratio or its related term are showing as below:

ABTI's Current Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2
* Ranked among companies with meaningful Current Ratio only.

Alterola Biotech  (OTCPK:ABTI) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Alterola Biotech Current Ratio Related Terms


Alterola Biotech Current Ratio Historical Data

* Premium members only.

The historical data trend for Alterola Biotech's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterola Biotech Current Ratio Chart

Alterola Biotech Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Mar22 Mar23 Mar24
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.04 0.12 0.02 0.00

Alterola Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.00 0.00 0.01 0.32

ABTI vs SKYI, GCAN, PNXP: Current Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alterola Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alterola Biotech Current Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alterola Biotech's Current Ratio distribution charts can be found below:

* The bar in red indicates where Alterola Biotech's Current Ratio falls into.



Alterola Biotech Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Alterola Biotech's Current Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Current Ratio (A: Mar. 2024 )=Total Current Assets (A: Mar. 2024 )/Total Current Liabilities (A: Mar. 2024 )
=0.004/1.333
=0.00

Alterola Biotech's Current Ratio for the quarter that ended in Sep. 2024 is calculated as

Current Ratio (Q: Sep. 2024 )=Total Current Assets (Q: Sep. 2024 )/Total Current Liabilities (Q: Sep. 2024 )
=1.147/3.615
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Current Ratio →
What does a Current Ratio of 0.32 mean?
Alterola Biotech (ABTI) has a Current Ratio of 0.32 as of Sep. 2024.
Is Alterola Biotech's Current Ratio too high?
Alterola Biotech's current Current Ratio is 0.32. The Drug Manufacturers industry median Current Ratio is 2.00. Alterola Biotech's value of 0.32 is 84% below this industry median.
How does Alterola Biotech's Current Ratio compare to SKYI and GCAN?
Alterola Biotech's Current Ratio of 0.32 can be compared against companies in the Drug Manufacturers industry. The industry median Current Ratio is 2.00. Alterola Biotech's value of 0.32 is 84% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alterola Biotech's current Current Ratio of 0.32 is 84% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alterola Biotech's current Current Ratio is 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterola Biotech stock overvalued right now?
Alterola Biotech (ABTI) has a current Current Ratio of 0.32. The current Current Ratio is 0.32 and 84% below the Drug Manufacturers industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Alterola Biotech (ABTI), the current Current Ratio is 0.32 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterola Biotech Business Description

Address 47 Hamilton Square, Birkenhead, Merseyside, GBR, CH41 5AR
Alterola Biotech Inc is a pharmaceutical company working with cannabinoid and cannabinoid-like molecules. The company operates in three focus areas: Development of regulated pharmaceuticals (human and animal health) and regulated food products; Production of low cost of goods Active Pharmaceutical Ingredient (API) and food-grade ingredients; and Formulation, and drug delivery, providing improved bioavailability, solubility and stability.